SRPT Earnings Sarepta Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–48 of 48
| Q2 2026 | 2026-06-30 | -0.05 | 2026-08-05 | 10-Q |
| Q1 2026 | 2026-03-31 | 2.88 | 2026-05-06 | 10-Q |
| Q4 2025 | 2025-12-31 | -3.93 | 2026-03-02 | 10-K |
| FY 2025 | 2025-12-31 | -7.13 | 2026-03-02 | 10-K |
| Q3 2025 | 2025-09-30 | -0.50 | 2025-11-06 | 10-Q |
| Q2 2025 | 2025-06-30 | 1.89 | 2025-08-06 | 10-Q |
| Q1 2025 | 2025-03-31 | -4.60 | 2025-05-06 | 10-Q |
| Q4 2024 | 2024-12-31 | 1.50 | — | — |
| FY 2024 | 2024-12-31 | 2.34 | 2025-02-28 | 10-K |
| Q3 2024 | 2024-09-30 | 0.34 | 2024-11-06 | 10-Q |
| Q2 2024 | 2024-06-30 | 0.07 | 2024-08-07 | 10-Q |
| Q1 2024 | 2024-03-31 | 0.37 | 2024-05-01 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | 0.79 | 2024-02-28 | 10-K |
| FY 2023 | 2023-12-31 | -5.80 | 2024-02-28 | 10-K |
| Q3 2023 | 2023-09-30 | -0.46 | 2023-11-01 | 10-Q |
| Q2 2023 | 2023-06-30 | -0.27 | 2023-08-02 | 10-Q |
| Q1 2023 | 2023-03-31 | -5.86 | 2023-05-02 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -1.24 | 2023-02-28 | 10-K |
| FY 2022 | 2022-12-31 | -8.03 | 2023-02-28 | 10-K |
| Q3 2022 | 2022-09-30 | -2.94 | 2022-11-02 | 10-Q |
| Q2 2022 | 2022-06-30 | -2.65 | 2022-08-02 | 10-Q |
| Q1 2022 | 2022-03-31 | -1.20 | — | — |
| FY 2021 | 2021-12-31 | -5.15 | — | — |
| Q3 2021 | 2021-09-30 | -0.60 | — | — |
| Q2 2021 | 2021-06-30 | -1.02 | — | — |
| FY 2020 | 2020-12-31 | -7.11 | — | — |
| Q2 2018 | 2018-06-30 | -1.67 | 2018-08-08 | 10-Q |
| Q1 2018 | 2018-03-31 | -0.55 | 2018-05-03 | 10-Q |
| Q4 2017 | 2017-12-31 | -0.37 | 2018-03-01 | 10-K |
| Q3 2018 | 2017-09-30 | -0.78 | — | — |
| Q2 2017 | 2017-06-30 | -1.15 | 2017-08-03 | 10-Q |
| Q1 2017 | 2017-03-31 | 1.50 | 2017-05-04 | 10-Q |
| Q2 2016 | 2016-06-30 | -1.35 | — | — |
| Q1 2016 | 2016-03-31 | -1.31 | — | — |
| Q3 2013 | 2013-09-30 | -1.24 | 2013-11-12 | 10-Q |
| Q2 2013 | 2013-06-30 | -0.60 | 2013-08-08 | 10-Q |
| Q4 2012 | 2012-12-31 | -2.36 | 2013-03-15 | 10-K |
| Q3 2012 | 2012-09-30 | -2.17 | 2012-11-07 | 10-Q |
| Q2 2012 | 2012-06-30 | 0.35 | 2012-08-07 | 10-Q |
| Q1 2012 | 2012-03-31 | -0.78 | 2012-05-10 | 10-Q |
| Q4 2011 | 2011-12-31 | -0.06 | — | — |
| FY 2011 | 2011-12-31 | -0.02 | 2012-03-13 | 10-K |
| Q3 2011 | 2011-09-30 | -0.18 | — | — |
| Q2 2011 | 2011-06-30 | 0.06 | 2011-08-08 | 10-Q |
| Q1 2011 | 2011-03-31 | 0.09 | — | — |
| FY 2010 | 2010-12-31 | -0.29 | — | — |
| Q2 2010 | 2010-06-30 | -0.15 | — | — |
| FY 2009 | 2009-12-31 | -0.27 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.